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Abstract
Background: Gastrointestinal stromal tumors (GIST) mutational status is recognized factor related to the results of
tyrosine kinase inhibitors therapy such as imatinib (IM) or sunitinib (SU). Arterial hypertension (AH) is common adverse
event related to SU, reported as predictive factor in renal cell carcinoma. The aim of the study was to analyze the
outcomes and factors predicting results of SU therapy in inoperable/metastatic CD117(+) GIST patients after IM failure.
Methods: We identified 137 consecutive patients with advanced inoperable/metastatic GIST treated in one center
with SU (2
nd line treatment). Median follow-up time was 23 months. Additionally, in 39 patients there were
analyzed selected constitutive single nucleotide polymorphisms (SNPs) of VEGFA and VEGFR2 genes.
Results: One year progression-free survival (PFS; calculated from the start of SU) rate was 42% and median PFS
was 43 weeks. The estimated overall survival (OS, calculated both from start of SU or IM) was 74 weeks and 51
months, respectively. One-year PFS was 65% (median 74 weeks) in 55 patients with AH vs. 22% (median 17 weeks)
in patients without AH. Patients with primary tumors carrying mutations in KIT exon 9 or wild-type had
substantially better 1-year PFS (68% and 57%; median 65.5 and 50.5 weeks, respectively) than patients having
tumors with KIT exon 11 or PDGFRA mutations (34% and 15%; median 36.8 and 9 weeks, respectively). We
identified two independent factors with significant impact on PFS and OS in univariate and multivariate analysis:
primary tumor genotype and presence of AH. The most common adverse events during therapy were: fatigue, AH,
hypothyroidism, hand and foot syndrome, mucositis, skin reactions, dyspepsia, and diarrhea. Two deaths were
assessed as related to tumor rupture caused by reaction to SU therapy. The presence of C-allele in rs833061 and
the T-allele in rs3025039 polymorphism of VEGFA were associated with significantly higher risk of hypothyroidism
(OR: 10.0 p = 0.041 and OR: 10.5; p = 0.015, respectively).
Conclusions: We confirmed that many advanced GIST patients benefit from SU therapy with OS > 1.5 year.
Primary tumor KIT/PDGFRA genotype and SU-induced AH, as surrogate of its antiangiogenic activity are two
independent factors influencing both PFS and OS.
Note: The preliminary data of this study were presented during Annual Meeting of American Society of Clinical
Oncology, 4-8 June 2011 and Connective Tissue Oncology Society Meeting, 26-28 October 2011 in Chicago, IL.
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Unprecedented improvement in advanced gastrointest-
inal stromal tumors (GIST management has been
achieved due to recent recognition of the important bio-
logical role of activating mutations in KIT and PDGFRA
(platelet-derived growth factor receptor- alpha) genes.
Those observations led to the introduction of imatinib
mesylate, a small-molecule selective inhibitor of the
receptor tyrosine kinases such as stem-cell factor recep-
tor (KIT, CD117), BCR-ABL and platelet-derived growth
factor receptors (PDGFRs)-A and -B. Imatinib revolutio-
nized the outcome of patients with advanced CD117-
positive GISTs and is currently approved as the first-line
treatment in advanced (metastatic and/or inoperable)
GISTs [1-5]. However, the spectacular response to ima-
tinib therapy is time-limited and secondary resistance to
imatinib therapy (after initial stabilization or response)
develops in majority of patients [4].
Currently, the only approved second-line drug is suni-
tinib malate - a multitargeted agent, an inhibitor of tyro-
sine kinase, of KIT and PDGFRA/B and of the vascular
endothelial growth factor receptors (VEGFRs)-1, -2 and
3, FMS-like tyrosine kinase-3 (FLT3), colony stimulating
factor 1 receptor (CSF-1R), and glial cell-line derived
neurotrophic factor receptor (REarranged during Trans-
fection; RET) [6-11]. Sunitinib possesses both antiangio-
genic and cytostatic properties and by competing with
ATP binding prevents multiple receptor tyrosine kinases
phosphorylation in vitro and in vivo.T w op h a s eI I ,o n e
phase III and one “treatment-use” trials have investi-
gated the activity of sunitinib in GIST patients after the
failure of prior imatinib treatment, and all these trials
have shown the significant activity of sunitinib in this
population of patients [11-14]. The objective clinical
benefit was achieved in approximately 60% of GIST
patients who received sunitinib after failure of prior
imatinib treatment [11-14]. Median progression -free
survival time on sunitinib is 6-8 months. The adverse
events reported during this therapy are frequent. The
most common treatment-related adverse events were
fatigue, diarrhea, skin discoloration, nausea, mucositis,
arterial hypertension, hand and foot syndrome (palmar-
plantar erythrodysesthesia), impairment of left ventricu-
lar ejection fraction and hypothyroidism [12,14].
Moreover, arterial hypertension was not only the com-
mon adverse event during sunitinib therapy, but it was
reported as predictive factor for results of renal-cell car-
cinoma (RCC) patients [15,16]. This phenomenon has
not been yet analyzed in GIST patients.
There is a lack of studies analyzing the outcome of
sunitinib in advanced GISTs after imatinib failure ther-
apy in routine practice outside clinical trials. Thus, the
aim of our study was to evaluate factors predicting
results and toxicity of SU second-line therapy in inoper-
able/metastatic GISTs. Additionally, we have investi-
gated the impact of the selected single nucleotide
polymorphisms (SNPs) in VEGFA and VEGFR2 genes
on sunitinib-related toxicity in the subgroup of patients.
Patients and Methods
Patients
We analyzed prospectively collected data of 137 conse-
cutive patients treated with sunitinib maleate because of
inoperable and/or metastatic CD117 positive GIST
enrolled into therapy between October, 2005 and Febru-
ary, 2011, reviewed in one tertiary cancer center. All
patients met the following criteria for sunitinib treat-
ment: 1) histological diagnosis of GIST, confirmed by
CD117-immunopositivity (DAKO; Carpintiera, CA), 2)
metastatic and/or inoperable lesions after failure on
prior treatment with imatinib (confirmed progressive
disease or unacceptable toxicity) 3) measurable disease
on computed tomography (CT) scans, 4) WHO perfor-
mance status ≤3, 5) no concomitant therapy for disease,
6) adequate renal, cardiac and liver function.
Each patient provided informed consent for the study
and collection of clinical and molecular data prior suni-
tinib therapy. The study had been approved by the local
Bio-Ethics Committee according to Good Clinical Prac-
tice Guidelines (approvals from Bio-Ethics Committees
from Medical University of Gdansk and from Maria
Sklodowska-Curie Memorial Cancer Center and Insti-
tute of Oncology, Warsaw KB/9/2011 and approval for
Polish Clinical GIST Registry by Internal Review Board
119/2002). Patients provided additional informed con-
sent for taking the 5 ml blood samples for gene poly-
morphisms analysis. Patients did not undergo any
further selection; 35 patients were initially included in
the treatment-use trial A6181036.
All patients were treated with sunitinib in initial
licensed dose of 50 mg daily in 6 weeks cycle (4 weeks
on/2 weeks off therapy), however the dosing could be
reduced (to 37.5 mg or 25 mg) or delayed or modulated
t ot h ed o s i n go f3 7 . 5m go nc o n t i n u o u ss c h e d u l et o
optimize the benefit-risk profile according to decision of
treating physician. The treatment was continued until
confirmed progression of the disease or unacceptable
toxicity. All patients were followed carefully with med-
ian follow-up time of 23 months (range: 6-68 months).
The objective response of GIST to sunitinib therapy was
evaluated with serial CT examinations (performed every
2-3 months), according to Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.0 [17]. In case of
progression, patients were treated with other different
tyrosine kinase inhibitors or cytotoxic chemotherapy or
best supportive care only. If possible, they were included
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were graded with National Cancer Institute common
toxicity criteria, version 3.0 [18].
Genotyping
Genomic screening was performed for the presence of
the KIT (exons 9, 11, 13, and 17) or PDGFRA (exons 12,
14 and 18) genes mutation in randomly selected 89
cases, based on DNA isolated from paraffin-embedded
or fresh frozen imatinib-naive tumor tissues, as pre-
viously described [19].
SNPs analysis
Genomic DNA was isolated from peripheral blood sam-
ples of 39 consenting patients using the standard proto-
col with proteinase K digestion, phenol - chloroform
extraction and ethanol precipitation. Three selected
VEGFA SNPs: rs699947 (-2578 C > A), rs3025039 (+936
C > T), and rs2010963 (+405 G > C) and two VEGFR2
(KDR) SNPs: rs1531289 (3405-92A > G) and rs1870377
(+1416 T > A) were genotyped using restriction frag-
ment length polymorphism (RFLP) method. The restric-
tion enzymes which detected - SNPs mentioned above
were BsaIII, BsmF1, NlaIII and AluI, respectively.
Amplified DNA was digested with endonucleases over-
night at optimal temperatures according to the manu-
facturer (Fermentas, Thermo Scientific) and then
electrophoresed on 2% agarose gel. For identification of
an additional VEGFA SNP: - rs833061 (460 T > C)
direct sequencing was performed using ABI 3100
Genetic Analyser (Applied Biosystems Inc. Foster City,
CA). Primers sequences and PCR cycling parameters are
available on request.
Statistical analysis
Contingency tables were analyzed by the chi-square test.
Progression-free survival (PFS) time was calculated from
the date of the start of sunitinib treatment to the date
of the most recent follow-up, or progression or death
due to the disease. Overall survival (OS) time was calcu-
lated either from the date of the start of imatinib and
sunitinib treatment to the date of the most recent fol-
low-up or death due to the disease [except cases of two
patients, whose death was attributed to adverse event
(AE) of sunitinib therapy]. PFS was assessed with respect
to the following variables: demographic data (age at the
diagnosis ≤ 45 or > 45 years; gender), primary tumor
genotype (KIT 11 exon, KIT 9 exon, any PDGFRA muta-
tions and wild-type cases), length of previous therapy on
imatinib (≤ 6, > 6-12, > 12 months), and presence of
arterial hypertension (defined as occurrence of systolic
blood pressure > 140 mm Hg or diastolic blood pressure
> 90 mm Hg, or deterioration of preexisting AH during
the first three months of therapy with sunitinib). The
Kaplan-Meier method was used for analysis of survival
curves, compared by log-rank test.
For univariate comparison of the survival between
groups, the Kaplan-Meier estimator was used with gen-
eralized Wilcoxon and the log-rank tests. For PFS/OS
comparisons in relation to presence of arterial hyperten-
sion two cases with early death due to tumor perfora-
tion were excluded to minimize the lead-time bias of
the results. In multivariate an a l y s i so ft h ef a c t o r sa s s o -
ciated with PFS and OS, we used Cox proportional
hazards models, applying the stepwise model building
procedure that included all covariates significant at 20%
level in bivariate analysis. Two-way interactions were
then considered in the model. Differences were consid-
ered statistically significant if p-values were < 0.05.
These statistical computations were performed using
Statistica 6.1 software [Statsoft
®; Tulsa, OK].
The Hardy-Weinberg equilibrium analysis of VEGFA
and VEGFR2 polymorphisms was performed using a
chi-square test with one degree of freedom. Multiplica-
tive, dominant and recessive models were tested in
every SNP for the associations with OS, PFS and treat-
ment AEs. Odds ratios (ORs) with their exact 95% con-
fidence intervals (CI) were calculated and the exact test
for OR was used. The polymorphisms analyses were
performed using StatXact-3 software, version 3.1.
Results
Clinicopathological data
The distribution of clinical and pathological data of
patients included in the study is listed in Table 1. There
were 74 male and 63 female patients, with median age
at the start of sunitinib therapy 55 years (range: 15 -
82). The majority of primary tumors were located in the
small intestine (57.6%), followed by the stomach (33.5%).
All but two patients had documented progression on
imatinib. Majority of patients (70.1%) were pre-treated
with imatinib for more than one year. Almost 90% of
patients started sunitinib therapy being in relatively
good performance status (0-1).
Mutational analysis data
The distribution of patients according to the initial
tumor mutational status is shown in Table 1. In the
group of 89 patients, whose initial tumor mutational sta-
tus was evaluated, 58.4% of GISTs had an exon 11 KIT
mutation, 16.9% had an exon 9 KIT mutation, 13.5%
had PDGFRA gene mutation (11 of 12 cases had D842V
mutation) and in 11.2% of tumors we have not detected
any mutations (wild-type).
Treatment toxicity
Adverse events were common during sunitinib treat-
ment (127/137 evaluated patients; 93%), and in 31.4% of
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most common non-hematological adverse events were:
fatigue (65%), arterial hypertension (43%), hand-foot
syndrome (40%), hypothyroidism (31%), skin/hair disco-
loration (30%), diarrhea (28%) and mucositis (25.5%).
The frequency of reported hematological toxicity was as
follows: anemia (37%), neutropenia (36%) and thrombo-
cytopenia (13%). Two deaths (grade 5) due to the tumor
rupture and hemorrhage were assessed as related to
reaction to sunitinib therapy (during 1
st month of ther-
apy). Additionally, three patients were operated due to
tumor perforation (bleeding/bowel perforation) also
attributed to reaction to sunitinib. For management of
drug toxicity sunitinib dose was reduced to 37.5/25 mg
in 44% of cases (60 patients).
Outcomes of sunitinib treatment
Median PFS was 43 weeks and estimated 1-year PFS
rate was 42%. Progression of disease during sunitinib
therapy was observed in 105 cases (77%). At the time of
the analysis, 45 patients (33%) were alive. Estimated 2-
year OS rate was 40% and median OS was 73.5 weeks.
Estimated 5-year OS in this group of patients was 45%
(when calculated from the date of imatinib start) and
median OS - 51 months.
The best responses observed during sunitinib therapy
and estimated by CT imaging (two consecutive exami-
nations) according to RECIST criteria were as follows:
none complete responses (CRs), 21 (15%) partial
responses (PRs), 62 (45%) stable disease (SD) at least
four months, 51 (37%) progressive disease (PD) and
three patients were not assessable for response. Overall
clinical benefit of sunitinib therapy (counted as the sum
of CR, PR and SD rates) was 60%.
Correlations between mutational status of primary GISTs
and response to sunitinib therapy
We have found a strong relationship (p < 0.001)
between the primary tumor genotype and best observed,
confirmed response to sunitinib according to RECIST
criteria: the best outcomes were observed for KIT exon
9 mutants (six PR - 40%, seven SD - 47%, two PD -
13%), followed by wild-type GISTs (seven SD - 70% and
three PD - 30%) and KIT exon 11 mutants (10 PR -
19%, 23 SD - 44%, 19 PD - 37%); the worst results of
sunitinib therapy were found in patients with PDGFRA
mutated GISTs (two SD - 17% and 10 PD - 82%).
Factors influencing PFS and OS during sunitinib therapy
In univariate analysis two factors significantly correlated
with shorter PFS and OS that were: tumor genotype:
exon 11 KIT or PDGFRA mutation (p = 0.04 and p =
Table 1 Characteristics of 137 patients treated with
sunitinib due to advanced GIST
Clinicopathological
features
No of
patients
(%)
Total number of patients 137 (100)
Age [years] at the start of
therapy with sunitinib
Median (range) 55 (15-82)
≤45 14 (10)
> 45 123 (88)
Gender Female 63 (46)
Male 74 (54)
Primary tumor site Stomach 46 (33.5)
small bowel 79 (57.6)
large bowel/rectum 4 (2.9)
other or intraperitoneally with
unknown primary origin
8 (5.8)
Time on imatinib therapy ≤ 6 months (early resistance) 25 (18.2)
6-12 months 16 (11.7)
> 12 months 96 (70.1)
Primary reason for stop of
imatinib therapy
Disease progression 135 (98.5)
Imatinib intolerance 2 (1.5)
ECOG Performance Status 0 48 (35)
1 72 (52.6)
≥2 17 (12.4)
Tumor genotype* Exon 11 KIT mutation 52 (58.4)
Exon 9 KIT mutation 15 (16.9)
PDGFRA mutation 12 (13.5)
Wild-type 10 (11.2)
Data not available 48
* mutational status was evaluated in 89 cases (65%)
Table 2 The most common adverse events (AEs) during
sunitinib therapy in the entire analyzed group of GIST
patients
Any grade Grade 3/4
AEs n%N %
Any treatment-related AE 127 92.7 43 31.4
Fatigue 89 65 12 8.7
Diarrhea 37 28 4 2.9
Hand-foot syndrome 55 40 3 2.2
Decreased appetite/dysgeusia 25 18.2 0 0
Mucositis 35 25.5 2 1.5
Hypertension 59 43 4 2.9
Neutropenia 49 36 7 5.1
Anemia 51 37 8 5.8
Skin/hair discoloration 41 30 0 0
Dyspepsia 43 31.4 0 0
Thrombocytopenia 18 13.1 3 2.2
Hypothyroidism 42 31 2 1.5
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hypertension during sunitinib therapy (p = 0.0001 and p
= 0.001) (Figure 2). We did not find any significant cor-
relation between PFS/OS and patients gender and age at
diagnosis, GIST primary tumor location, WHO perfor-
mance status 0 vs. 1, or time on previous imatinib treat-
ment. Estimated 1-year PFS and 2-year OS according to
primary tumor genotype were as follows: KIT exon 9
mutations - 68%/73% (median 65.5/151.5 weeks), wild
type - 57%/70% (median 50.5/121 weeks), KIT exon 11
mutations - 34%/34% (median 36.8/65.5 weeks) and
PDGFRA mutations - 15%/25% (median 9/40 weeks).
Patients with presence of arterial hypertension during
first three months of sunitinib therapy had substantially
better 1-year PFS and 2-year OS than patients without
this adverse event (65% vs. 22%, and 63% vs. 18%; med-
ian 77 vs. 25.5 weeks, and 128.5 vs.4 3w e e k s ,
respectively).
In the multivariate analysis two factors (tumor geno-
type and arterial hypertension) had independent predic-
tive value for PSF and OS (Tables 3 and 4).
Genetic variations of VEGFA and VEGFR2 genes
T h eg e n o t y p ef r e q u e n c yo fVEGFA/VEGFR2 gene SNPs
are presented in Table 5. All analyzed genotypes were in
Hardy-Weinberg equilibrium. The higher risk of
hypothyroidism during sunitinib therapy was associated
with: C-allele in rs833061 (OR: 10.l; p = 0.041) and T-
allele in rs3025039 (OR: 10.5; p = 0.015) (Table 6). We
did not find the correlation between the presence of
SNPs and arterial hypertension, hand-foot-syndrome,
skin toxicity/mucositis or diarrhea (data not shown).
Discussion
A majority of patients with advanced GISTs ultimately
stop responding to imatinib and unquestionably
management of disease resistant to first-line treatment
represents a clinical challenge [4]. Insights into resis-
tance mechanisms have allowed developing several stra-
tegies in patients with progression during imatinib
treatment. In case of generalized progression (or intoler-
ance to imatinib) the main option is using monotherapy
with alternative multi-tyrosine kinase inhibitor - suniti-
nib, which remains the only approved second line drug
for the treatment of advanced GISTs after imatinib ther-
apy failure [20]. Sunitinib has demonstrated robust clini-
cal effectiveness in imatinib-resistant or -intolerant
GIST as shown in randomized, placebo-controlled phase
III trial in which the median time to tumor progression
for patients treated with sunitinib was more than four
times longer than that for patients receiving placebo
(27.3 vs. 6.4 weeks) [12]. Present study, according to our
best knowledge, represents of the largest series of GIST
patients after imatinib failure analyzed for the outcome
of sunitinib treatment in routine clinical practice outside
randomized, controlled clinical trial.
We have also attempted to prove tumor genotype
implications and to find new predictive factors in this
group of patients. We have confirmed that many
Figure 1 Overall survival during sunitinib therapy according to
primary tumor mutational status.
Figure 2 Progression-free survival during sunitinib therapy
according to presence of arterial hypertension.
Table 3 Multivariate analysis of prognostic factors for
progression-free survival
Hazard
ratio
95% CI Standard
Error
zp
value
Arterial
hypertension
Yes
0.2025 0.1097 -
0.3739
0.0633 -5.11 0.000
Primary tumor
mutation Wild
type
0.3292 0.1447 -
0.7491
0.1381 -2.65 0.008
PDGFRA
mutation
1.8753 0.9096 -
3.8661
0.0692 1.70 0.049
Rutkowski et al. BMC Cancer 2012, 12:107
http://www.biomedcentral.com/1471-2407/12/107
Page 5 of 9advanced GIST patients benefit from sunitinib therapy
(mainly due to stabilization of disease according to
RECIST, not Choi criteria [21]) with OS exceeding 1.5
years. The median PFS longer than seven months is
almost equal to the results of the Korean one-institu-
tion study [22]. We have also confirmed in more
detailed way and on the larger group of patients, than
ever published, data regarding the correlation between
primary tumor mutational status and sunitinib treat-
ment outcomes [22-24]. As for imatinib, KIT mutation
status appears to serve as a predictor of tumor
response to sunitinib. We have proven that, contrary
to imatinib, tumors initially (pre-imatinib treatment)
bearing KIT exon 9 mutation or with wild-type geno-
type have a higher chance to respond to sunitinib.
Moreover, GISTs harboring KIT exon 9 mutations
appear to be more sensitive to sunitinib than those
with primary KIT exon 11 mutations (however we
have observed some objective responses also in this
group of patients). The clinical benefit of sunitinib in
wild-type cases is also clear. We have not observed any
response to sunitinib in group of patients with
PDGFRA mutations (mainly D842V), which has been
also shown in preclinical data. We did not analyze the
impact of secondary mutations, although patients from
clinical trials with tumors harboring a secondary muta-
tion in exon 13 or exon 14 KIT have a longer PFS
than patients with exon 17 or 18 mutations [23,25-27].
On the other hand, utility of analysis of secondary
mutations is very challenging because imatinib-
resistant GISTs are very heterogeneous with multiple
clones having different secondary mutations within the
same or different nodules [28-30].
Sunitinib therapy is associated with several adverse
events, which were generally mild to moderate and could
be managed by dose modulation (including continuous
administration of lower dose) [20,22,24]. The toxicity
profile reported in our study is similar to that observed
in clinical trials, with exception of hypothyroidism, which
occurred in more than 30% of patients (it has been
reported outside clinical trials [31,32]). However, up to
one third of cases were classified as more severe toxicity
(and two deaths due to tumor hemorrhage were classified
as related to sunitinib therapy). Our own experience with
patients with unresectable or metastatic GISTs, treated
with tyrosine kinase inhibitors, suggested the higher inci-
dence of emergency operations for gastrointestinal bleed-
ing, bowel obstruction, or abscess, occur during second-
line therapy with sunitinib than during first-line therapy
with imatinib [33,34]. This increased incidence of compli-
cations leading to surgical interventions with sunitinib
could be associated with the presence of more advanced
and drug-resistant disease, or to the direct mechanism of
action of sunitinib, i.e., the combination of cytotoxic and
antiangiogenic activity, leading to dramatic tumor
response.
Arterial hypertension is one of the most common com-
plications of sunitinib therapy, occurring usually early
after treatment initiation. Serial monitoring of blood pres-
sure is recommended during therapy with sunitinib.
Table 4 Multivariate analysis of prognostic factors for overall survival
Hazard ratio 95% CI Standard Error z p value
Primary tumor
mutation Exon 9 KIT mutation
0.7491 0.3308 - 1.6968 0.3125 -0.69 0.489
PDGFRA mutation 1.2678 0.5487 - 2.9327 0.5425 0.55 0.579
Wild-type 0.1029 0.0317 - 0.3336 0.0618 -3.79 0.000
Arterial hypertension
Yes
0.2056 0.1006 - 0.4201 0.0749 -4.34 0.000
CI confidence interval
Table 5 The genotype frequency of VEGFA/VEGFR2 genes SNPs and Hardy-Weinberg equilibrium (HWE) test results
Polymorphism rs number Genotype (%) HWE exact p value Frequency of risk allele
Homozygous (wild) Heterozygou Homozygous (mutant)
VEGFA
-2578 C > A rs699947 32.4 54.1 13.5 0.73 0.41
-460 T > C rs833061 29.7 45.9 24.3 0.74 0.47
936 C > T rs3025039 75.7 24.3 - 1.00 0.12
405 G > C rs2010963 24.3 40.5 35.1 0.32 0.55
VEGFR2 (= KDR)
3405-92A > G rs1531289 48.6 45.7 5.7 0.69 0.29
1416 T > A rs1870377 53.1 40.6 6.3 1.00 0.27
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biomarker of antitumor efficacy (probably by antiangio-
genic mechanism), because it was an independent factor
influencing patient both progression-free and overall sur-
vival. Antiagiogenic activity may play an important role
in therapy of sarcomas, what has been recently confirmed
by positive results of phase III trial with pazopanib in
pre-treated soft tissue sarcoma patients [35]. Similar rela-
tionships between arterial hypertension induced by VEGF
inhibitors (including sunitinib) and oncological outcomes
have been reported in renal cell carcinoma patients
[15,16,36-39]. Treatment-induced persistent hypertension
was associated with frequent tumor response, a long time
to disease progression and longer overall survival [39].
Clinical outcomes are not compromised by treatment
with anti-hypertension medications, moreover, patients
who required at least three antihypertensive drugs had
t h el o n g e s tP F Sa n dO S[ 3 8 ] .T h e r ea r ep r o p o s e ds o m e
hypothetical mechanisms leading to hypertension related
to sunitinib, e.g. presence of less-perfused microvessels
and/or diminished number of microvessels, decreasing
nitric oxide production and activation of the endothelin-1
pathway leading to vasoconstriction [40,41].
I nt h es u b g r o u po fp a t i e n t sw eh a v ea n a l y z e ds o m e
possible pharmacogenetical relationships with sunitinib
tolerance. It has been shown that single nucleotide poly-
morphisms of VEGF and VEGFR2 genes has some
potential as biomarkers for clinical outcomes and toxi-
city of VEGF pathway targeted therapy [42-46]. We
have not studied correlation between SNPs of VEGFA/
VEGFR genes and outcomes of therapy due to limited
number of cases, but we have found clear associations
between two SNPs of VEGFA gene and sunitinib-
induced hypothyroidism. The molecular mechanisms of
hypothyroidism induced by sunitinib are unknown, but
recent studies have suggested that VEGFR inhibition
can induce vasculature regression in various organs, pre-
dominantly in thyroid, what can be linked to different
properties of VEGF protein caused by gene polymorph-
isms and sunitinib sensitivity [47,48].
Conclusions
To summarize, we confirmed that many advanced GIST
patients benefit from sunitinib therapy with overall survi-
val exceeding 1.5 year. Exploring the toxicity of multi-
kinase targeting agents in GISTs may allow better
adjusted therapy as well as to define novel pharmacody-
namics markers. Primary tumor genotype and sunitinib-
induced arterial hypertension (as surrogate of its antian-
giogenic activity) are two independent factors influencing
the progression-free survival and OS. The mechanism of
side effects and its correlation with pharmacogenetic data
during sunitinib therapy need further studies.
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